Alogliptin-Induced Minimal Change Nephrotic Syndrome and Interstitial Nephritis
Alogliptin is one of the dipeptidyl peptidase-4 inhibitors used to treat patients with type 2 diabetes. Little is known about the nephrotoxicity associated with alogliptin, such as nephrotic syndrome or interstitial nephritis. We report a biopsy-proven rare case of minimal change nephrotic syndrome...
Main Authors: | Hisato Shima, Takuya Okamoto, Manabu Tashiro, Tomoko Inoue, Chiaki Masaki, Hiroaki Tada, Norimichi Takamatsu, Kazuhiko Kawahara, Kazuyoshi Okada, Toshio Doi, Jun Minakuchi, Shu Kawashima |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-03-01
|
Series: | Kidney Medicine |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590059519300202 |
Similar Items
-
Cilostazol-induced acute tubulointerstitial nephritis accompanied by IgA nephropathy: a case report
by: Hisato Shima, et al.
Published: (2018-03-01) -
Drug-induced interstitial nephritis in a child with idiopathic nephrotic syndrome
by: Printza Nikoleta, et al.
Published: (2009-01-01) -
Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients
by: Hisato Shima, et al.
Published: (2018-06-01) -
Alogliptin: efficiency, safety, new possibilities
by: L. Yu. Morgunov
Published: (2020-05-01) -
CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN
by: N. A. Petunina, et al.
Published: (2017-12-01)